BiofutureRx Information

BioFutureRx is a biopharmaceutical company focused on biologic medicines. We concentrate on the areas of biologic medicine where differentiated science and development expertise can widen access and address unmet need — biosimilars, first-in-class and novel antibodies, companion diagnostics, and drug-delivery platforms. Alongside that focus, we develop our own peptide therapeutics in-house. Our lead asset, BFRx3711, is a proprietary long-acting GLP-1 analog engineered for potential once-monthly dosing in obesity and type 2 diabetes — designed to compete for the convenience segment beyond today's weekly therapies. We also help biologics companies reach the United States. Drawing on an affiliated network with decades of U.S. and Canadian in-licensing experience, we act as a single U.S. counterpart — navigating the FDA pathway, structuring the partnership, securing supply, and reaching patients — to turn an ex-U.S. program into an American product. Partnering and investment inquiries: info@biofuturerx.com · biofuturerx.com